Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Dermira will focus on developing the IL-13 inhibitor in atopic dermatitis, where it sees an opportunity for potential dosing and efficacy benefits. Roche had focused on respiratory disease, with mixed results.

Medical dermatology specialist Dermira Inc. plans to refocus development of the interleukin-13 inhibitor lebrikizumab on the treatment of atopic dermatitis after taking control of the program from Roche. Despite growing competition in the therapy area, Dermira sees an opportunity for lebrikizumab to become a best-in-class agent, with potential efficacy and dosing convenience benefits.

The company announced Aug. 8 that it signed a licensing deal with Roche to gain worldwide rights to develop and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.